Top Abstract Purchase Related
Home
>
Node
>
Subnode

Managlinat dialanetil, a fructose-1,6-bisphosphatase inhibitor for the treatment of type 2 diabetes

Wang, Y.; Tomlinson, B.

Current Opinion in Investigational Drugs 8(10): 849-858

2007

ISSN/ISBN: 1472-4472
PMID: 17907062
Document Number: 608293
Metabasis Therapeutics Inc (formerly Gensia Sicor Inc, which became SICOR Inc), in collaboration with Daiichi Sankyo Co Ltd (formerly Sankyo Co Ltd) is developing the fructose-1,6-bisphosphatase inhibitor managlinat dialanetil, a low-molecular weight purine nucleotide analog that inhibits gluconeogenesis, for the potential treatment of type 2 diabetes. Phase II clinical trials of the compound are underway in Europe and the US.

Document emailed within 1 workday
Secure & encrypted payments

Costas, M.J.; Cameselle, J.C. 1988: The inhibition of fructose 1,6-bisphosphatase by fructose 2,6-bisphosphate is enhanced by EDTA and diminished by zinc(II) Biochemistry International 16(4): 747-753
Skrypal', I.G.; Iastrebova, O.V. 2002: Fructose-bisphosphatase of microorganisms Mikrobiolohichnyi Zhurnal 64(2): 82-94
Martínez, J.; Cid, H. 1986: A model for the structure of fructose-1,6-bisphosphatase from pig kidney Archivos de Biologia y Medicina Experimentales 19(1): 77-83
Lee, H.; Kwon, A.; Kim, H.-S.; Lee, J.-S. 2019: Fructose-1,6-bisphosphatase deficiency presented with complex febrile convulsion Neuro Endocrinology Letters 39(8): 533-536
Pfaller, W.; Thorwartl, U.; Nevinny-Stickel, M.; Krall, M.; Schober, M.; Joannidis, M.; Hobisch, A. 1994: Clinical value of fructose 1,6 bisphosphatase in monitoring renal proximal tubular injury Kidney International. Supplement 47: S68-S75
Ballícora, M.A.; D'Alessio, A.C.; Mora-García, S.; Rodríguez-Suarez, R.J.; Wolosiuk, R.A. 1998: The reductive modulation of chloroplast fructose-1,6-bisphosphatase by tributylphosphine and sodium borohydride Cellular and Molecular Biology 44(3): 431-437
Maheshwari, V.; Bhardwaj, R.; Sharma, D.; Nagar, S. 1988: Heterogeneous photochemical and chloroplasts mediated activation of spinach fructose-1,6-bisphosphatase Biochemical and Biophysical Research Communications 152(2): 668-673
Reyes, A.; Rodríguez, P.; Slebe, J.C. 1992: The interaction of monovalent cations with fructose 1,6-bisphosphatase modified by N-ethylmaleimide and its relation with AMP inhibition Biochemistry International 26(2): 347-356
Kaiser, S. 1998: Cell volume regulates liver phosphoenolpyruvate carboxykinase and fructose-1,6-bisphosphatase genes American Journal of Physiology 274(3): G509-G517
Mykhalchenko, V.G.; Minchenko, D.O.; Tsuchihara, K.; Moenner, M.; Komisarenko, S.V.; Bikfalvi, A.; Esumi, H.; Minchenko, O.H. 2008: Expression of mouse 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 mRNA alternative splice variants in hypoxia Ukrains'kyi Biokhimichnyi Zhurnal 80(1): 19-25
Fehmann, H.C. 2000: Treatment of type 2 diabetes mellitus with the alpha-glucosidase inhibitor Miglitol in the doctor's office Fortschritte der Medizin. Originalien 118 Suppl. 2: 55-61
Fehmann, H.C. 2001: The alpha-glucosidase inhibitor miglitol for the treatment of type 2 diabetes mellitus in the doctor's office Fortschritte der Medizin. Originalien 119 Suppl. 2: 55-61
Minchenko, D.O.; Kundieva, A.V.; Tsuchihara, K.; Yavorovsky, O.P.; Paustovsky, Y.O.; Esumi, H.; Minchenko, O.H. 2009: Expression of 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase-3 and VEGF mRNA in rat liver, lung and heart: effect of methyl tertbutyl ether Ukrains'kyi Biokhimichnyi Zhurnal 81(4): 59-68
Skrypal', I.H.; Tokovenko, I.P.; Malynovs'ka, L.P. 2005: Effect of silver nitrate, adenosine-5'-monophosphate and phosphoenolpyruvate on activity of extracellular fructose bisphosphatase of Acholeplasma laidlawii var. granulum strain 118 Mikrobiolohichnyi Zhurnal 67(4): 28-34
Zidek, W. 2004: Diabetes and Nephropathy: ACE inhibitor for type 1, AT1 blocker for type 2 MMW Fortschritte der Medizin 146(42): 51-52
Scheen, A.J. 2015: Empagliflozin (Jardiance) :nw Sglt2 Cotransporter Inhibitor for Treating type 2 Diabetes Revue Medicale de Liege 70(9): 472-479
Kalra, S. 2011: Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes Journal of the Association of Physicians of India 59: 237-245
Davì, G.; Belvedere, M.; Vigneri, S.; Catalano, I.; Giammarresi, C.; Roccaforte, S.; Consoli, A.; Mezzetti, A. 1996: Influence of metabolic control on thromboxane biosynthesis and plasma plasminogen activator inhibitor type-1 in non-insulin-dependent diabetes mellitus Thrombosis and Haemostasis 76(1): 34-37
Scheen, A.J. 2005: Similar reduction in new cases of type 2 diabetes with angiotensin receptor blocker and ACE inhibitor: comparison of meta-analyses of prospective randomised trials Revue Medicale de Liege 60(5-6): 424-428
Miller, E.M. 2017: Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Role of Injectable Medications in Type 2 Diabetes Treatment Journal of Family Practice 66(10 Suppl): S4-S6